Does Fibre-fix provided to people with irritable bowel syndrome who are consuming a low FODMAP diet improve their gut health, gut microbiome, sleep and mental health? A double-blinded, randomised controlled trial by Yan, Ran et al.
Edith Cowan University 
Research Online 
ECU Publications Post 2013 
2020 
Does Fibre-fix provided to people with irritable bowel syndrome 
who are consuming a low FODMAP diet improve their gut health, 
gut microbiome, sleep and mental health? A double-blinded, 
randomised controlled trial 
Ran Yan 
Mandy Murphy 
Angela Genoni 
Evania Marlow 
Ian Dunican 
See next page for additional authors 
Follow this and additional works at: https://ro.ecu.edu.au/ecuworkspost2013 
 Part of the Medicine and Health Sciences Commons 
10.1136/bmjgast-2020-000448 Yan, R., Murphy, M., Genoni, A., Marlow, E., Dunican, I. C., Lo, J., ... & Christophersen, 
C. T. (2020). Does Fibre-fix provided to people with irritable bowel syndrome who are consuming a low FODMAP 
diet improve their gut health, gut microbiome, sleep and mental health? A double-blinded, randomised controlled 
trial. BMJ Open Gastroenterology, 7(1), Article e000448. http://dx.doi.org/10.1136/bmjgast-2020-000448 
This Journal Article is posted at Research Online. 
Authors 
Ran Yan, Mandy Murphy, Angela Genoni, Evania Marlow, Ian Dunican, Johnny Lo, Lesley Andrew, Amanda 
Devine, and Claus T. Christophersen 
1Yan R, et al. BMJ Open Gastro 2020;7:e000448. doi:10.1136/bmjgast-2020-000448
Does Fibre- fix provided to people with 
irritable bowel syndrome who are 
consuming a low FODMAP diet 
improve their gut health, gut 
microbiome, sleep and mental health? A 
double- blinded, randomised 
controlled trial
Ran Yan  ,1 Mandy Murphy,1 Angela Genoni,1 Evania Marlow,1 Ian C Dunican,1 
Johnny Lo,2 Lesley Andrew,1 Amanda Devine,1 Claus T Christophersen  1,3
To cite: Yan R, Murphy M, 
Genoni A, et al. Does Fibre- 
fix provided to people with 
irritable bowel syndrome who 
are consuming a low FODMAP 
diet improve their gut health, 
gut microbiome, sleep and 
mental health? A double- 
blinded, randomised controlled 
trial. BMJ Open Gastro 
2020;7:e000448. doi:10.1136/
bmjgast-2020-000448
Received 19 May 2020
Revised 4 July 2020
Accepted 6 July 2020
1School of Medical and 
Health Sciences, Edith Cowan 
University, Joondalup, Western 
Australia, Australia
2School of Science, Edith 
Cowan University, Joondalup, 
Western Australia, Australia
3WA Human Microbiome 
Collaboration Centre, School 
of Molecular & Life Sciences, 
Curtin University, Perth, Western 
Australia, Australia
Correspondence to
Ran Yan;  r. yan@ ecu. edu. au
Irritable bowel syndrome
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published 
by BMJ.
ABSTRACT
Introduction A diet low in fermentable oligosaccharides, 
disaccharides, monosaccharides and polyols (FODMAP) 
is an effective way to reduce gut symptoms in people 
with irritable bowel syndrome (IBS). This diet reduces the 
intake of fermentable fibres, leading to changes of the 
gut microbiota and insufficient fermentation in the large 
bowel, resulting in reduced production of short- chain fatty 
acids (SCFAs), such as butyrate, which has unfavourable 
implications for gut health, sleep and mental health. This 
study will examine the effect of Fibre- fix, a supplement 
containing a mix of dietary fibres, on the human gut 
microbiome composition, fermentative capacity, sleep, 
quality of life (QOL) and mental health of people with IBS 
who consume a low FODMAP diet (LFD).
Methods and analysis A randomised, double- blind, 
placebo- controlled, study design is proposed to examine 
whether Fibre- fix added to an existing LFD may help 
modulate gastrointestinal function, improve markers of 
sleep, mental health and promote QOL in patients with 
IBS. Participants will provide stool and blood samples, 
daily bowel symptoms diaries and 3- day diet records. 
Additionally, they will complete validated questionnaires 
relating to FODMAP intake, sleep, mental health and QOL 
before and after a 3- week intervention. Gut health will 
be assessed via faecal microbiome composition, faecal 
pH and SCFA levels. Alteration of sleep will be recorded 
using an actigraphy device worn by all participants over 
the whole study. Multivariate analysis will be used to 
examine the gut microbiome and repeated measures 
Analysis of variance (ANOVA) will be used for dependent 
variables from questionnaires related to bowel symptoms, 
stool type, sleep, mental health and QOL to assess the 
differences between intervention and control groups after 
adjustment for confounding variables.
Ethics and dissemination Ethics approval was obtained 
from the Human Research Ethics Committee of Edith 
Cowan University (2019-00619- YAN). Results will be 
disseminated in peer- review journal publications, and 
conference presentations. Participants will be provided 
with a summary of findings once the study is completed. 
If Fibre- fix is shown to result in favourable changes in gut 
microbial composition, SCFA production, sleep and mental 
well- being without exacerbating symptoms, this will 
provide additional dietary management options for those 
with IBS following an LFD.
Trial registration number ACTRN12620000032954.
INTRODUCTION
Irritable bowel syndrome (IBS) is one of 
the most frequently diagnosed functional 
gastrointestinal disorders, affecting approx-
imately 11.2% of the global adult popula-
tion.1 2 Diagnosis of IBS is challenging due 
to the subjective nature of digestive symp-
toms and is currently based on the Rome 
IV criteria.3 This functional disorder typi-
cally presents with recurrent abdominal 
pain with alterations in bowel habits, namely 
stool consistency and frequency, coexisting 
bloating, flatulence and abdominal disten-
tion. The syndrome is subtyped into four 
patterns: IBS with predominant constipa-
tion or predominant diarrhoea, mixed IBS 
and un- subtyped.4 Due to the dominance of 
chronic symptoms and frequently present 
comorbidities, somatic and psychological, 
IBS imposes a heavy burden on individuals 
and communities both economically and 
socially.5 6 Of those employed, patients with 
IBS reported 24.3% absenteeism and 86.8% 
presentism, due to their syndrome.7 In two 
independent studies it were estimated that 
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IBS- related absenteeism and presenteeism cost industry 
£400–£9008 or to €937–€2108 annually.9
A diet that is low in fermentable oligosaccharides, disac-
charides, monosaccharides and polyols (FODMAP)10 
alias a low FODMAP diet (LFD), is an effective dietary 
intervention for IBS. A blinded and placebo- controlled 
trial found that approximately three- quarters of patients 
with IBS benefit from an LF.11 The LFD reduces food 
(fibre) compounds that are poorly absorbed in the small 
intestine, rapidly fermentable in the proximal colon, 
and thereby contribute to the gastroenterological symp-
toms. The LFD includes a selective elimination diet for 
2–6 weeks followed by a reintroduction phase of FODMAP 
containing foods followed by personalisation of a diet 
that minimises symptoms.12 13 Despite the positive effects 
of the LFD in reducing gut symptoms and improving 
quality of life (QOL) in those with IBS, it only treats the 
symptoms of IBS. Studies suggest potentially negative 
impacts of long term adherence to an LFD, including 
nutritional inadequacy, potential increased risk of gastro-
intestinal complications and imbalance of the gastroin-
testinal microbiome.12 14 15 Evidence from both animal 
and human studies has demonstrated that a low intake of 
dietary fibres can reduce microbiota diversity leading to 
increased cancer risk.16–19 Reintroduction or restoration 
of dietary fibres to an LFD diet can be difficult with whole 
food due to the coexistence of a range of fibres in indi-
vidual foods. This study therefore reintroduces dietary 
fibre using a supplement however this process should 
be done gradually and continuous, otherwise unwanted 
symptoms such as gas, flatulence and cramps may impact 
adherence.
Research suggests a low FODMAP intake rapidly and 
negatively changes the gut microbial community, abun-
dance and diversity.15 20 21 In healthy people, a 1- week LFD 
resulted in an alteration of the gut microbiota, reduced 
beneficial bacteria such as Actinobacteria, predomi-
nantly Bifidobacterium, and a lower overall total bacterial 
count.22 After a 4- week LFD, Bennet et al23 observed an 
increased dysbiosis manifested as altered gut microbial 
fermentation leading to lower total short- chain fatty acid 
(SCFA) concentrations24 in patients with IBS. Addition-
ally, a randomised, cross- over trial comparing LFD with a 
standard Australian diet15 found a marked reduction in 
butyrate‐producing Clostridium cluster XIVa and cluster 
IV, favourable mucus- associated Akkerkmansia muciniphila, 
and an increase in mucus- detrimental Ruminococcus 
torques. In another study, Bifidobacterium and Faecalibacte-
rium prausnitzii associated with butyrate production were 
significantly decreased following a 3- week LFD.25 Taken 
together these results suggest the lack of fibre associated 
with LFD may explain the microbial changes. Human 
gut microbiota is able to recognise and degrade different 
forms of complex carbohydrate.26–28 A diet rich in 
dietary fibres with different extents of fermentability and 
solubility is recommended, which means more varied 
and complex dietary fibres in the diet leads to a more 
dynamic, diverse and stable gut microbiota.29 Various 
purified dietary fibres are capable of nourishing specific 
gut bacteria, such as Bifidobacteria, F. prausnitzii and Eubac-
terium hallii.26 30–32 Dietary fibre improves the human gut 
microbiota by providing a substrate for fermentation, 
and subsequently increases production of SCFA. It is well 
established in the literature that higher levels of SCFA can 
be obtained from a higher intake of fermentable dietary 
fibres.19 33 34 Butyrate, one of the major SCFA throughout 
the colon, provides the primary fuel for colonic cells to 
maintain growth and integrity and thereby improve gut 
health.35–37 Furthermore, research suggests that butyrate 
can positively affect circadian rhythm regulation38 39 and 
enhance sleep via interplay between gut and brain.40 
Therefore, this study will increase the amount of fibre 
in the diet of patients with IBS to restore the gut micro-
biome and its metabolite profile to potentially prevent 
increasing the risk of patient’s developing other more 
severe gastrointestinal diseases.
Thirty- three per cent of patients with IBS reported they 
had sleep problems, such as sleep fragmentation, poor 
sleep quality, reduced sleep time and frequent awak-
ening.41 42 Disordered sleep or sleep disturbances are 
also recorded with a greater prevalence in IBS sufferers 
compared with healthy individuals.43 44 Despite unknown 
causal relationship between impacted sleep and IBS, the 
close association between gastrointestinal symptoms and 
sleep disturbances has been identified by others.45–47 The 
gut microbiota is suggested to play a pivotal role and 
affect multiple mechanisms in this complex relationship 
between human sleep disturbances and gastrointestinal 
disease.48 49 Smith et al50 found that gut microbial diver-
sity was positively associated with total sleep time, as well 
as sleep efficiency which also were positively correlated 
with phyla richness of Bacteroidetes and Firmicutes. 
Their findings indicate that an diet intervention repre-
sent a promising way to improve sleep by manipulating 
the gut microbiota to promote sleep- related phyla and 
taxa in the human gut microbiome.50 In addition, it has 
been suggested that gut microbial composition could be 
altered by sleep fragmentation, resulting in a 50% reduc-
tion in Actinobacteria and 20% in Bacteroidetes, but a 
20% increase in Firmicutes, which is similar to the micro-
bial profile of obese individuals.51 52
Many research studies have demonstrated the signif-
icant association between IBS and mental health, even 
though the causation relationship is still unclear. A 
meta- analysis of Guillaume Fond et al53 concluded that 
patients with IBS were more likely to develop depression 
and anxiety than healthy volunteers groups, whereas 
Sibelli et al54 found that depression and anxiety doubled 
the risk of IBS onset. It is estimated that 44% of patients 
with IBS have associated mental health conditions, such 
as depression and anxiety.55 Patients with IBS have been 
observed with gut microbial alterations related to depres-
sion, including greater rates of kynurenine (a deleterious 
metabolite of tryptophan), an elevated kynurenine/tryp-
tophan ratio,56 and declined Lactobacillus and Bifidobacte-
rium which are also less abundant in patients with major 
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depressive disorder.57 Clostridia, a major class within the 
phylum Firmicutes, appears at increased abundance in 
patients with IBS.58 59 This link to an animal study showing 
abundance of Clostridia were significantly higher after 
stress- related stimuli in stress- vulnerable rats compared 
with stress- resilient rats.60 Demonstrating that gut micro-
bial communities respond to stress differently among 
animals with distinct stress vulnerability. Furthermore, 
the researchers suggest a Bacilli to Clostridia ratio can 
reflect stress effects, with a higher value indicating less 
stress- derived inflammatory reactions.60
Some inflammatory markers in human blood are asso-
ciated with both human gut health and mental health 
and provide a potential mechanism for the role of 
dietary fibre in mitigating mental health. A randomised 
controlled trial in patients with serious depression demon-
strated serum concentration of high- sensitivity C reactive 
protein (hs- CRP) and scores of Beck Depression Inven-
tory questionnaire significantly decreased after taking a 
probiotic supplement (Lactobacillus spp and Bifidobacte-
rium bifidum).61 Additionally, proinflammatory cytokines, 
like tumor necrosis factor alpha (TNF-α), interleukin 
(IL-6) and IL-1β, are able to cross the blood- brain barrier 
(BBB), and their entry and following influences can 
have a negative effect on mental health.62 The entry of 
the cytokines, however, can be reduced by improving the 
integrity of blood brain barrier. The permeability of BBB 
can be decreased by the SCFA butyrate which is produced 
in the gut via gut bacterial fermentation of fermentable 
carbohydrate residue escaping from small intestinal 
digestion.63
In summary, a healthier gut microbiota altered by 
a dietary fibre intervention or supplement in patients 
with IBS may not only improve gut health but also sleep, 
mental health and QOL. The objective of this research 
study is to determine, in patients with diagnosed IBS and 
on an LFD, whether Fibre- fix, compared with a placebo 
control, improves gut microbial composition, faecal 
SCFA levels, sleep quality, QOL, markers inflammation 
and of mental well- being, without exacerbation of IBS 
symptoms. This study will be the first to explore the bidi-
rectional relationship between dietary fibres supplement 
and sleep modulated by the gut microbiota in patients 
with IBS following the LFD.
METHODS AND ANALYSIS
Study design
The study is designed as a randomised, double- blinded, 
placebo- controlled trial, with a 3- week intervention 
period (figure 1). The total time required for participant 
involvement is 4 weeks, including a 1- week baseline and a 
3- week intervention.
Sample size
The a priori sample size for the proposed study was deter-
mined based on the results obtained by McOrist et al,64 
where a sample size of 50 participants (25 per group) 
was required to detect a change in log SCFA concentra-
tion of 0.4 at 80% power and 5% level of significance. 
Allowing for a 15% drop- out rate, the total sample size 
of 58 subjects, 29 per group is required. This sample 
size is sufficient to detect at least a medium between- 
within group interaction effect (Cohen’s f=0.25) in sleep 
improvement at 80% power and 5% significance level, 
whereby the corresponding sample size requirement is 
34.
Participants
Fifty- eight people (n=58) with IBS on an LFD will be 
recruited. Participants must be between 18 and 65 years 
old and have been clinically diagnosed with IBS, using the 
Rome IV edition diagnostic criteria65 by a gastroenterolo-
gist or other medical professional. Participants will be on 
an LFD for 1 month prior to the intervention. Addition-
ally, participants will need to be available to attend the 
local clinic visits and be willing to consume the Fibre- fix 
supplement or matched placebo.
Participants will be excluded if they are current 
smokers; pregnant or planning to become pregnant; 
have a known diagnosis of other gastrointestinal illness 
(eg, inflammatory bowel disease, malabsorption of any 
macronutrients, bowel resection, coeliac disease); have 
had previous abdominal or gastrointestinal surgeries, 
severe mental health and sleep- related conditions (eg, 
insomnia), renal or hepatic diseases, and major medical 
illness; currently use pharmaceutical agents that could 
modify or treat IBS (eg, probiotics, antibiotics, eluxad-
oline, lubiprostone and linaclotide) or sleep conditions; 
follow other restrictive dietary patterns or therapies (eg, 
low- carbohydrate, keto/Paleo- diet); take any prebiotics; 
Figure 1 Flow chart showing study design overview.
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have any other disease, condition or habit that may inter-
fere with completion of study.
Recruitment
Participants will be recruited through networks of regis-
tered Western Australian based dietitians and gastroen-
terologists who will be provided with information flyers to 
promote the study to potential participants. Information 
flyers will be posted on websites including social media 
groups relating to IBS or FODMAP. A university webpage 
will advertise study information.
Allocation, blinding and compliance
A computer- generated list of random numbers provided 
by a statistician will be used to randomly assign partici-
pants to either the intervention or control group. The 
participants will receive a resealable snap- lock bag, 
labelled A or B, containing 40 sachets of either Fibre- fix 
or placebo. Both participant and researcher will be 
blinded from the group allocation. Bag labelling will be 
completed by an independent person. The participants 
will be required to return unused sachets to calculate 
compliance. An online daily checklist, together with a 
weekly text/email reminder, will be provided to partic-
ipants to record time of consuming the intervention; a 
daily tick- list/calendar will be created for participants to 
follow. Consumption of >80% of the sachets (32 sachets) 
during the 3- week period will be considered compliant.
Intervention
Fibre- fix consists of one soluble dietary fibre and one 
insoluble fermentable fibre, which will be provided 
to participants in 40 separate sachets with gradually 
increasing amount (table 1). After baseline data collec-
tion, participants will be required to consume Fibre- fix as 
per the labels on the sachets, one sachet per day for the 
first 2 days and two for the remaining 19 days according 
to the schedule (table 1). For participants’ convenience, 
all sachets have been labelled with day and time (AM or 
PM) on the package, for example DAY 3 AM, and will be 
provided orderly in resealable plastic bags. The placebo 
sachet contains a combination of the same soluble dietary 
fibre and highly digestible fibre and will be delivered in 
the same way as the intervention.
Primary outcomes
Faecal SCFA and gut microbiota
Faecal SCFA levels and gut microbiota will be assessed 
through 24 hours stool samples which will be obtained at 
baseline and at the end of the intervention. Participants 
will be provided with the stool collection kit, including a 
portable cooler bag, frozen icepacks and an instruction 
sheet. All stool samples collected with the 24 hours 
period will be pooled and homogenised if the number 
of individual samples is more than one. On receipt, stool 
samples will be immediately weighed and stored at −80°C. 
Individual’s samples will be thawed at 4°C and kept at this 
temperature during homogenised and aliquoting for all 
planned analysis and re- frozen at −80°C until analyses.
The concentrations of bacterial metabolites in faeces, 
such as SCFA (acetate, propionate and butyrate) will be 
determined by gas chromatography.66 In brief, an acid-
ified aqueous methanol solution will be used to extract 
SCFA from faecal samples, followed by separating SCFA 
by gas chromatography with a fatty acid column using a 
Thermo Scientific TG- Wax column(30 m x 0.25 mm x 
0.25 μm). The SCFA level will be qualified via internal 
standards.
Microbial analyses will be performed at the WA Human 
Microbiome Collaboration Centre, Curtin University, 
Western Australia. DNA will be extracted using the 
QIAamp PowerFecal DNA kit (Qiagen) using Qiacube 
extraction platform. Microbiome signatures are gener-
ated using the Illumina MiSeq platform using uniquely 
barcoded 16S rRNA gene primers (515-806(V4)) for 
bacterial and ITS2 primers for fungal profiling (pending 
on funding), following PCR inhibition assessment of each 
DNA extract. PCR- free ligation protocol is thereafter 
deployed for the process of library building. Samples 
will be sequenced to a depth of minimum 50 000 reads, 
which is sufficient to identify microbes to a genus/species 
level. Quality control and mock community samples 
are included in the analysis from sample collection 
to sequence analysis. Sequence read quality is initially 
assessed with FastQC before demultiplexing and prepro-
cessing by GHAPv2, an in- house tool. Cutadapt67 is used 
for removal of all non- biological sequences. DADA268 is 
then used for quality filtering, error correction, amplicon 
sequence variants (ASVs) picking. A trained naïve bayes 
classifier then assigns ASVs to genus/species against a 
curated database of microbial reference sequences such 
as the Ribosomal Database Project (RDP)69 or Genome 
Taxonomy Database.70 For fungal classification the 
UNITE database71 will be used.
Secondary outcomes
Objective measures of sleep
Participants will be provided with the Readiband V.5 
(Readiband, Fatigue Science, Canada), a wrist- activity 
monitor that has been validated and objectively assesses 
sleep using accelerometery.72 Compared against polysom-
nography—the gold standard of sleep measurement, the 
wrist- activity monitor does not require laboratory setup 
Table 1 Grams of dietary fibre supplement in each sachet provided to participants during 3- week interventional period
Day 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
AM 5 5 5 5 10 10 10 20 20 20 20 20 20 20 20 20 20 20 20 20 20
PM \ \ 5 5 10 10 10 10 10 10 20 20 20 20 20 20 20 20 20 20 20
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nor trained personnel.72 Moreover, the Readiband can 
automatically identify time at lights out using a propri-
etary algorithm, which not only eases the burden of sleep 
diary but also avoids the potential bias from self- reported 
data of recalling time for bed.72 This technology has been 
widely applied to the sleep- related research.73–76 Partici-
pants will be required to wear the monitor on the non- 
dominant wrist for 24 hours per day during the study. The 
monitor- derived sleep measure data will be downloaded 
via the automated Readiband Sync software (table 2).
Subjective measures of sleep
Participants will be required to complete five validated 
questionnaires related to sleep at baseline, and at the end 
of the intervention.
Pittsburgh Sleep Quality Index
The Pittsburgh Sleep Quality Index (PSQI) retrospec-
tively assesses sleep quality and relevant disturbances over 
the previous month. This self- administrated question-
naire has been validated in a population- based setting to 
measure sleep quality. The summary score is calculated 
as the summation of 19 items grouped into seven compo-
nents, ranging from 0 (better) to 21 (worse); a score >5 
indicates poor sleep quality.77
Epworth Sleepiness Scale
The Epworth Sleepiness Scale (ESS) is a self- rated eight- 
item questionnaire, designed to measure daytime sleep-
iness.78 Participants score each question from 0 (high 
chance of dozing) to 3 (would never doze), which yield a 
global score of ESS ranging from 0 to 24. Scores higher 
than nine reflect excessive daytime sleepiness and severe 
problems with daytime somnolence.79
Insomnia Severity Index
Insomnia will be assessed through the self- reported 
Insomnia Severity Index (ISI) comprising seven items. 
Participants are required to rate each question on a 
5- point Likert scale as per their own experience over 
the past 2 weeks. The total score ranges from 0 to 28, 
and represents clinical insomnia when it is higher than 
14.80
Sleep Hygiene Index
The Sleep Hygiene Index (SHI) is a self- reported instru-
ment for assessing individual behaviours in sleep hygiene. 
The 13 items that comprise SHI are rated on a 5- point 
Likert scale and produce a total score ranging from 0 to 
52 with higher scores representing poorer status of sleep- 
behavioural hygiene.81
Restorative Sleep Questionnaire weekly version
The Restorative Sleep Questionnaire weekly version 
(RSQ- w) is composed of nine questions completed on 
restorative aspects of the sleep during the past week, and 
whose reliability and validity has been published.82 Each 
item scales from one to five. The first two items and the 
last item are reversed scored. The total score ranging 
Table 2 Definitions of sleep measures as extracted from the Readiband (Fatigue Science, Canada) device, based on Dunican 
et al72
Sleep measures Acronym Units Abbreviated Measurement Description
Time at Lights Out TALO Time of day hh:mm Directly 
measured
Time at Sleep Onset minus Sleep Onset 
Latency.
Sleep Onset Latency SOL Minutes min Derived Number of minutes from Time at Lights 
Out to Time at Sleep Onset.
Time at Sleep Onset TASO Time of day hh:mm Directly 
measured
Time of day when the first epoch of sleep 
occurs between Time at Lights Out and 
Time at Wake.
Time at Sleep Onset 
Variance
TASOV Minutes min Derived Time at Sleep Onset consistency relative 
to mean Time at Sleep Onset.
Sleep Duration SD Minutes min Derived Number of minutes from Time at Sleep 
Onset to Time at Wake, minus number of 
minutes awake (WASO).
Wake After Sleep 
Onset
WASO Minutes min Directly 
measured
Number of minutes awake after Time at 
Sleep Onset.
Fragmentation Index FI Frequency number Directly 
measured
Number of awakenings between Time at 
Sleep Onset and Time at Wake.
Time at Wake TAW Time of day hh:mm Directly 
measured
Time of day when awake with no further 
Sleep Duration.
Time in Bed TIB Minutes min Derived The total time spent in bed, from Time at 
Lights Out to Time at Wake.
Sleep Efficiency SE Percentage % Derived Sleep Duration divided by Time in Bed 
multiplied by 100.
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from 0 to 100, calculates as: (RSQ- w average score across 
completed items−1)×25. The higher total scores indicate 
better restorative sleep.
Mental health and QOL assessment
The condition of mental health and QOL in both groups 
will be assessed using in total four validated question-
naires at baseline and at the end of the intervention.
Depression Anxiety Stress Scale
The Depression Anxiety Stress Scale (DASS-21) is a vali-
dated self- reported questionnaire designed to measure 
three subscales which are depression, anxiety and stress 
with seven items for each dimension.83 Higher scores 
are indicative of poorer mental condition and severity of 
symptoms, but the DASS-21 is not a clinically diagnostic 
instrument. Nonetheless, DASS-21 has broad applica-
bility and free availability and has been validated among 
the general population and for patients with chronic 
disease.84 85
Scores above 14, 10 and 17 in the three dimensions 
indicate severe depression, anxiety and stress, respec-
tively. In such instances, participants will be referred to 
their medical practitioner for clinical care.
Visceral Sensitivity Index
The Visceral Sensitivity Index (VSI) is a validated self- 
reported questionnaire and will be employed to measure 
gastrointestinal specific anxiety. The total VSI score is 
generated from all 15 items, each defined on a 6- point 
Likert scale. Patients with a higher score will be regarded 
as experiencing severe gastrointestinal symptom- specific 
anxiety.86 87
IBS Quality of Life
For assessment of participants’ QOL, IBS- QOL question-
naire will be used at the stages of baseline clinic, prior 
to and after intervention. The IBS- specific question-
naire is a validated measurement tool, generating one 
total and eight subscale scores with 34 items covering 
dysphoria, interference with activity, body image, health 
worry, food avoidance, social reaction, sexual activity and 
relationships.88
WHO (Five) Well-Being Index
WHO (Five) Well- Being Index (WHO-5) is a validated 
self- reported questionnaire consisting of five items 
that measures mental well- being in relation to the past 
2 weeks. Responders rate each item on a 6- point Likert 
scale. The result will be calculated by multiplying the raw 
total score, ranging from 0 to 25, by four. The higher 
scores represent those with a better imaginable well- being 
condition.89
All questionnaires will be collated in the software 
Qualtrics and administered online to reduce participant 
burden.
Demographic information
Participants will complete a demographic questionnaire 
which requires personal information: gender, age, nation-
ality, marital status, area of residence, mobile number, 
email address, smoking history, alcohol consumption, 
birth delivery mode, dietary pattern and physical activity.
Anthropometric measurements
Participants’ height (cm) and weight (kg) will be 
measured to the nearest 0.1 cm and 0.1 kg, respectively, 
by an SECA 763 digital column scale (SECA, USA), where 
circumferences of waist and hips will be measured in 
accordance with international operating procedures for 
anthropometric assessment.90 Body mass index (BMI) 
and waist/hip ratio will be calculated.91 Percentage of 
lean and fat mass will be obtained using the BOD POD 
(Cosmed, Rome, Italy), an Air Displacement Plethysmo-
graph using whole body densitometry, to determine body 
composition (fat vs lean % fat mass),92 and conducted 
following manufacturer protocols for measurement. This 
will require subjects to fast for 8 hours prior to testing and 
wear tightly fitted gym clothes for measurement. Blood 
pressure (mm Hg) will be measured using an Omron 
IA1B Automated Blood Pressure Device (Omron Health-
care, Japan). All measurements will be carried out at 
baseline and end of intervention.
Blood biomarkers
The venous blood samples will be collected after an over-
night fast at baseline and at the end of the intervention. 
Blood samples will be centrifuged and processed within 
half an hour after collection for separating plasma and 
serum, and frozen at −80°C after being aliquoted into 
2 mL vials. Analysis of fasting lipids, glucose and glycated 
haemoglobin will be performed by a pathology labora-
tory in accordance with the protocols from the National 
Association of Testing Laboratories. The outcome 
measures of hs- CRP, TNF-α, IL-6 and IL-1β will be anal-
ysed if funding is made available.
Gut symptoms
Participants will complete a bowel symptom question-
naire at baseline and postintervention to assess changes in 
symptom severity. The questionnaire consists of Gastroin-
testinal Symptom Rating Scale for IBS (GSRS- IBS)93 and 
the IBS Severity Scoring System (IBS- SSS),94 which have 
been validated in clinical trials. The 13- item GSRS- IBS 
uses a 7- point Likert scale for severity of symptoms char-
acteristic of IBS including abdominal pain, diarrhoea, 
constipation and bloating satiety. This instrument is short 
and simple, and will assist researchers to determine the 
specific symptoms encountered by patients.93 The IBS- 
SSS point, with a maximum of 500 (100 for each item), is 
also used for classification of patients as remission (<75), 
mild (75–175), moderate (176–300) or severe (>300). 
Participants will use a visual analogue scale to score each 
of the five questions regarding symptom severity which 
include pain severity and duration, abdominal distention, 
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bowel dysfunction and QOL. For this study, a reduction 
of more than 50 points of IBS- SSS is defined as symptoms 
improvement.13
Daily Symptoms checklist
Each participant will be provided with an online daily 
bowel symptom checklist to report the sachet- consuming 
time and daily symptoms throughout the entire study 
period (Adapted from the not for profit, International 
Foundation for Functional Gastrointestinal Disorders 
(IFFGD) Personal Daily Diary: https:// aboutibs. org/ 
symptom- diary. html). The checkbox items include 
Bristol stool chart type, time and amount of fibre added 
to meals, bowel movement number of motions, stress 
level and menstrual cycle. Adverse symptoms monitoring, 
scoring symptoms (0–10), will be reported by partici-
pants daily and include abdominal pain, constipation, 
diarrhoea, bloating, flatus, eructation, headache, nausea 
and vomiting.
Food records
Dietary intake will be assessed using a 3- day weighed 
food record preintervention and postintervention. This 
will be completed by participants via a free downloaded 
smart- phone application, Research Food Diary (Xyris, 
Queensland, Australia). Participants will be provided 
with a set of scales (Propert, Supertex Industries) 
and instructed on the correct recording methods for 
weighed diet records. The Monash University Compre-
hensive Nutrition Assessment Questionnaire will be 
used to specifically quantify individuals’ FODMAP 
intake.
Table 3 schedule of primary and secondary endpoints 
that will be measured over the study.
Statistical analyses
Baseline participant demographics and primary and 
secondary outcome variables will be described and 
compared for differences by group. Descriptive statistics 
in the form of mean±SD will be used to describe contin-
uous variables, and frequencies and proportions for 
nominal and ordinal variables. All continuous outcome 
and demographic variables will be examined normality 
using the Shapiro- Wilk test. Median±IQR range will be 
presented instead for non- normal continuous variables.
Change in individual and total SCFA levels and faecal 
pH, will be examined using mixed- model Analysis of 
variance (ANOVA) between- groups and within- groups. 
Covariates, including gender and age, will be entered 
into the model as confounders. To analyse the gut 
microbiota profiles, multivariate analysis, Primer7 and 
PERMANOVA+ (PRIMER- E, Plymouth) and various R 
packages, will be used. Principal coordinates analysis 
will be deployed to visualise data. Distance- based linear 
Table 3 Study assessment schedule
Study item
Baseline 
period
3- week dietary intervention
Post- interventionW1 W2 W3
Demographic information ✓         
BMI, body fat, waist/hip ratio ✓       ✓
Gut symptoms questionnaire (IBS- SSS+GSRS IBS) ✓       ✓
Pittsburgh Sleep Quality Index ✓       ✓
Epworth Sleepiness Scale ✓       ✓
Sleep Hygiene Index ✓       ✓
Insomnia Severity Index ✓       ✓
Restorative Sleep Questionnaire weekly version ✓       ✓
Depression Anxiety Stress Scale ✓       ✓
Visceral Sensitivity Index ✓       ✓
IBS- Quality of Life ✓       ✓
WHO (Five) Well- Being Index ✓       ✓
Monash University: Comprehensive Nutrition 
Assessment Questionnaire
✓       ✓
Blood sample ✓       ✓
Stool sample ✓       ✓
Three- day diet record (via research food diary) ✓       ✓   
Sleep monitor—Readiband wrist wearable device ✓ ✓ ✓ ✓   
Daily symptoms checklist   ✓ ✓ ✓ ✓   
BMI, body mass index; GSRS- IBS, Gastrointestinal Symptom Rating Scale for irritable bowel syndrome; IBS- SSS, irritable bowel syndrome 
Severity Scoring System.
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models and distance- based redundancy analysis will be 
used to integrate microbiome findings with clinical, diet 
intake, immune function and other relevant data that 
might help explain the relationship between the micro-
biome findings and other outcomes. If a significant rela-
tionship or difference is established at the multivariate 
level, multiple linear regression (MLR) will be conducted 
at the univariate level to determine the association 
between the gut microbiota composition and SCFA levels, 
faecal pH, diet intake, sleep, mental health. The covari-
ates including gender, age, intervention compliance and 
IBS subtype will be considered as confounding variables 
and are adjusted in the MLR modelling. False discovery 
rate correction will be applied to account for testing of 
multiple outcomes.
For the effect of Fibre- fix on IBS symptomology, depen-
dent variables (DV) from the Bristol Stool Chart type and 
symptom severity scores collected from daily symptom 
checklist will be examined by group. Differences 
between- groups and within- groups in these outcomes 
will be assessed using mixed- model repeated measures 
ANOVA, adjusting for sex and age. The DV from the 
questionnaires for sleep, mental health and QOL include 
PSQI, ESS, ISI, SHI, RSQ- w, DASS-21, VSI, IBS- QOF and 
WHO-5 will be analysed in the same way as mentioned 
above.
All data analyses, other than the microbiome multivar-
iate data, will be conducted using SPSS V.25.0.95 Signif-
icance level is set at p≤0.05. Cohen’s effect size will be 
presented, where appropriate, to provide a measure prac-
tical/clinical significance.
DISCUSSION
The double- blinded, randomised controlled trial aims to 
examine whether Fibre- fix, in patients with IBS following 
an LFD, can improve gut microbiome composition, faecal 
SCFA concentrations, sleep quality, QOL and mental 
well- being, without exacerbation of IBS symptoms. Nega-
tive impacts on the gut microbiota of the LFD have been 
emerging, despite positive effects on IBS symptoms 
control.12 Therefore, how to maintain a low level of IBS 
symptoms and concurrently improve the gut microbiome 
requires further research. Fibre- fix, a combination of 
fibres, may improve gut health of IBS subjects through 
greater distal fermentation in the colon. This combination 
may avoid triggering IBS symptoms, promote gut fermen-
tation and SCFA (particularly butyrate) production which 
increases the biosynthesis and metabolism of neurotrans-
mitters that could improve sleep and mental conditions. If 
Fibre- fix can improve the gut microbiota as expected, this 
will propose a long- term dietary solution for those with IBS. 
The proposed mental health and sleep benefits may have a 
flow- on effect in terms of lowering the occurrence of other 
comorbidities, such as depression, anxiety and work absen-
teeism, which have economic benefits. In addition, if the 
cost- effective dietary fibre administration is well- tolerated, 
it may also significantly lower the economic and mental 
burden originating from IBS comorbidities on patients, 
the healthcare system as well as the wider community.
Limitations
This is the first study to assess the effects of Fibre- fix on 
patients with IBS and as a result there are limitations 
which broadly include: time, funding and participants’ 
burden. Specifically, this study will not explore hormonal 
changes relating to melatonin and serotonin caused by 
the dietary fibre supplement which may be helpful to 
further understand the mechanism and association of 
gut- brain axis. Moreover, the long- term effects of dietary 
fibre supplement will not be determined in this study 
because the study period is four weeks (1- week baseline 
and 3- week intervention). The gut microbiome and its 
metabolite profile (SCFA) are primary outcomes in this 
study as they will be valuable predictors of an improved 
gut health because of the reactive nature of the gut 
microbiome to diet changes. Therefore, such changes 
can be used to predict the value of Fibre- fix in lowering 
the risk of more severe gastrointestinal diseases in the 
future, but such findings would need to be validated in a 
long- term study. For sleep assessment, this study does not 
apply polysomnography. Therefore, changes in specific 
sleep stages will not be available, despite abnormality in 
rapid- eye movement among patients with IBS has been 
reported.96 Future studies would therefore be required 
to explore the long- term and mechanistic relationship 
between human gut health, diet, sleep and mental health.
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